Synthesis of new compounds bearing methyl sulfonyl pharmacophore as selective COX-2 inhibitor

被引:3
|
作者
Almarsoomi, Taha [1 ]
Osmaniye, Derya [1 ,2 ]
Saglik, Begum Nurpelin [1 ,2 ]
Levent, Serkan [1 ,2 ]
Ghani, Usman [3 ]
Ozkay, Yusuf [2 ]
Kaplancikli, Zafer Asim [1 ]
机构
[1] Anadolu Univ, Fac Pharm, Dept Pharmaceut Chem, TR-26470 Eskisehir, Turkiye
[2] Anadolu Univ, Fac Pharm, Cent Res Lab MERLAB, Eskisehir, Turkiye
[3] King Saud Univ, Coll Med, Dept Pathol, Clin Biochem Unit, Riyadh, Saudi Arabia
关键词
cyclooxygenase; dithiocarbamate; molecular docking; thiazole; DYNAMICS; SIMULATIONS; DERIVATIVES;
D O I
10.1002/jmr.3025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclooxygenase, also known as prostaglandin H2 synthase (PGH2), is one of the most important enzymes in pharmacology because inhibition of COX is the mechanism of action of most nonsteroidal anti-inflammatory drugs. In this study, ten thiazole derivative compounds had synthesized. The analysis of the obtained compounds was performed by H-1 NMR and C-13 NMR methods. By this method, the obtained compounds could be elucidated. The inhibitory effect of the obtained compounds on cyclooxygenase (COX) enzymes was investigated. The encoded compounds 5a, 5b, and 5c were found to be the most potent compared to the reference compounds ibuprofen (IC50 = 5.589 +/- 0.278 mu M), celecoxib (IC50 = 0.132 +/- 0.004 mu M), and nimesulide (IC50 = 1.692 +/- 0.077 mu M)against COX-2 isoenzyme. The inhibitory activity of 5a, 5b, and 5c is approximate, but the 5a derivative proved to be the most active in the series with an IC50 value of 0.180 +/- 0.002 mu M. The most potent COXs inhibitor was 5a, which was further investigated for its potential binding mode by a molecular docking study. Compound 5a was found to be localized at the active site of the enzyme, like celecoxib, which has a remarkable effect on COXs enzymes.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety
    Saglik, Begum Nurpelin
    Osmaniye, Derya
    Levent, Serkan
    Cevik, Ulviye Acar
    Cavusoglu, Betul Kaya
    Ozkay, Yusuf
    Kaplancikli, Zafer Asim
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 209
  • [2] Design, Synthesis and Biological Evaluation of New N-Acyl Hydrazones with a Methyl Sulfonyl Moiety as Selective COX-2 Inhibitors
    Osmaniye, Derya
    Saglik, Begum Nurpelin
    Levent, Serkan
    Ozkay, Yusuf
    Kaplancikli, Zafer Asim
    CHEMISTRY & BIODIVERSITY, 2021, 18 (11)
  • [3] Lumiracoxib (Prexige®):: a new selective cox-2 inhibitor
    Mysler, E
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) : 606 - 611
  • [4] The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis
    Schiffmann, Susanne
    Sandner, Jessica
    Schmidt, Ronald
    Birod, Kerstin
    Wobst, Ivonne
    Schmidt, Helmut
    Angioni, Carlo
    Geisslinger, Gerd
    Groesch, Sabine
    JOURNAL OF LIPID RESEARCH, 2009, 50 (01) : 32 - 40
  • [5] Rofecoxib: A selective COX-2 inhibitor
    不详
    Drugs & Therapy Perspectives, 2000, 15 (2) : 1 - 5
  • [6] A convenient synthesis of the key intermediate of selective COX-2 inhibitor Etoricoxib
    Tartaggia, Stefano
    Caporale, Andrea
    Fontana, Francesco
    Stabile, Paolo
    Castellin, Andrea
    De Lucchi, Ottorino
    RSC ADVANCES, 2013, 3 (40) : 18544 - 18549
  • [7] Clinical pharmacology of the selective COX-2 inhibitor
    Burian, M
    Geisslinger, G
    ORTHOPADE, 2003, 32 (12): : 1078 - +
  • [8] Etoricoxib: A highly selective COX-2 inhibitor
    Martina, SD
    Vesta, KS
    Ripley, TL
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (05) : 854 - 862
  • [10] Etodolac: An overview of a selective COX-2 inhibitor
    Jones R.A.
    InflammoPharmacology, 1999, 7 (3) : 269 - 275